In this review:
Abiraterone acetate + prednisolone for hormone-naive prostate cancer
PSMA-targeted, bispecific T-cell engager immune therapy
Olaparib for mCRPC with homologous recombination repair gene alterations
VERU-111 oral tubulin inhibitor for mCRPC after androgen blocking agent failure
Abiraterone + dexamethasone in mCRPC
BRCA2 status and intraductal and cribriform histologic variants
Ipatasertib + abiraterone for mCRPC
Cancer vaccine + PD-1 checkpoint blockade for mCRPC
Tolerability of olaparib in mCRPC patients
Please login below to download this issue (PDF)